Proteomic analysis of aortae from human lipoprotein(a) transgenic mice shows an early metabolic response independent of atherosclerosis

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Rodger, Euan J ^a   Suetani, Rachel J ^a   Jones, Gregory T ^a   Kleffmann, Torsten ^a   Carne, Alan ^a   Legge, Michael ^a   McCormick, Sally P A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STRUCTURAL PROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; FEMALE; FOAM CELL; FUNCTIONAL PROTEOMICS; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WILD TYPE; ANIMAL; AORTA; ATHEROSCLEROSIS; BIOLOGY; BLOOD; C57BL MOUSE; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; PROTEOMICS;

MUS; MUS MUSCULUS;

ANIMALS; AORTA; ATHEROSCLEROSIS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84855998419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030383     Document Type: Article

References (37)

1. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
2. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, et al. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353.
3. Zhang SH, Reddick RL, Piedrahita JA, Maeda N, (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471.
4. Linton MF, Farese RV Jr, Chiesa G, Grass DS, Chin P, et al. (1993) Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest 92: 3029-3037.
5. Meir KS, Leitersdorf E, (2004) Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 24: 1006-1014.
6. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B, (2007) Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 389: 1017-1031.
7. Julka S, Regnier F, (2004) Quantification in proteomics through stable isotope coding: a review. J Proteome Res 3: 350-363.
8. Rabilloud T, Chevallet M, Luche S, Lelong C, (2010) Two-dimensional gel electrophoresis in proteomics: past, present and future. J Proteomics 73: 2064-2077.
9. Mayr M, Chung YL, Mayr U, Yin X, Ly L, et al. (2005) Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 25: 2135-2142.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307.
12. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
13. Utermann G, (1989) The mysteries of lipoprotein(a). Science 246: 904-910.
14. Danesh J, Collins R, Peto R, (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102: 1082-1085.
15. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, et al. (2008) Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 168: 598-608.
16. Suk Danik J, Rifai N, Buring JE, Ridker PM, (2006) Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296: 1363-1370.
17. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG, (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117: 176-184.
18. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, et al. (2006) Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47: 2219-2228.
19. Tsimikas S, Witztum JL, (2008) The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19: 369-377.
20. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, et al. (1992) Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360: 670-672.
21. Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, et al. (1992) Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem 267: 24369-24374.
22. Callow MJ, Stoltzfus LJ, Lawn RM, Rubin EM, (1994) Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc Natl Acad Sci U S A 91: 2130-2134.
23. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM, (1995) Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 96: 1639-1646.
24. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, et al. (1995) Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 15: 1911-1916.
25. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP, (1995) Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41: 246-255.
26. Bartels ED, Lauritsen M, Nielsen LB, (2002) Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 51: 1233-1239.
27. Williamson KS, Hensley K, Floyd RA, (2003) Fluorometric and Colourimetric Assessment of Thiobarbituric Acid-Reactive Lipid Aldehydes in Biological Matrices. In: Hensley K, Floyd RA, editors. Methods in Pharmacology and Toxicology: Methods in Biological Oxidative Stress Totowa, NJ, USA Humana Press Inc.
28. Forstermann U, (2008) Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338-349.
29. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, et al. (2009) Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res 104: e42-54.
30. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, et al. (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7: 699-705.
31. Makowski L, Hotamisligil GS, (2005) The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 16: 543-548.
32. Shmueli O, Horn-Saban S, Chalifa-Caspi V, Shmoish M, Ophir R, et al. (2003) GeneNote: whole genome expression profiles in normal human tissues. C R Biol 326: 1067-1072.
33. Yvan-Charvet L, Wang N, Tall AR, (2010) Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 30: 139-143.
34. Feil S, Hofmann F, Feil R, (2004) SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. Circ Res 94: 863-865.
35. Shen J, Yang M, Ju D, Jiang H, Zheng JP, et al. (2010) Disruption of SM22 promotes inflammation after artery injury via nuclear factor kappaB activation. Circ Res 106: 1351-1362.
36. Berg K, Svindland A, Smith AJ, Lawn RM, Djurovic S, et al. (2002) Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis 163: 99-104.
37. Schneider M, Witztum JL, Young SG, Ludwig EH, Miller ER, et al. (2005) High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res 46: 769-778.